Form 4 filings across 2 companies. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: -$15.5M
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 5 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 9 most recent Form 4 transactions.
| RPRX |
| Royalty Pharma plc |
| SSELL◷ |
| 29,400 |
| $56.44 |
| $1.7M |
| -42.0% |
| Open the original filing on SEC.gov |
| Jun 30 | RPRX | Royalty Pharma plc | SSELL◷ | 2,554 | $57.10 | $145.8K | -0.5% | Open the original filing on SEC.gov |
| Jun 30 | RPRX | Royalty Pharma plc | SSELL◷ | 97,446 | $56.50 | $5.5M | -17.4% | Open the original filing on SEC.gov |
| Jun 23 | RPRX | Royalty Pharma plc | SSELL◷ | 117,592 | $54.47 | $6.4M | -17.4% | Open the original filing on SEC.gov |
| Jun 23 | RPRX | Royalty Pharma plc | SSELL◷ | 32,408 | $54.11 | $1.8M | -4.6% | Open the original filing on SEC.gov |
| May 6 | RPRX | Royalty Pharma plc | AGRANT | 24,263 | — | — | +3.5% | Open the original filing on SEC.gov |
| Apr 16 | KLRA | Kailera Therapeutics, Inc. | AGRANT◆ | 38,300 | — | — | — | Open the original filing on SEC.gov |